Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard therapy for cancer patients with activating BRAF mutations. However, the anti-tumorigenic effect and clinical benefit are only transient, and tumors are prone to treatment resistance and relapse. To elucidate mechanistic insights into drug resistance, we have established an in vitro cellular model of MAPK inhibitor resistance in malignant melanoma. The cellular model evolved in response to clinical dosage of BRAF inhibitor, vemurafenib, PLX4032. We profiled transcriptomic changes using RNA-Seq and RT-qPCR arrays. Pathways of melanogenesis, MAPK signaling, cell cycle, and metabolism were significantly enriched among the set of differentially expressed genes of vemurafenib-resistant cells vs control. The transcriptomic changes were validated in two distinct melanoma models, SK-MEL-28 and A375. Both cell lines have activating BRAF mutations and display metastatic potential. Downregulation of tumor suppressors and negative MAPK regulators, dual specific phosphatases, reengages mitogenic signaling. Upregulation of growth factors or cytokine receptors triggers signaling pathways circumventing BRAF blockage. Changes in amino acid and one-carbon metabolism support cellular proliferation despite MAPK inhibitor treatment. In addition, an upregulation of pigmentation in inhibitor resistant melanoma cells was observed. Cellular pathways utilized during inhibitor resistance promoted melanogenesis, a pathway which partially overlaps with MAPK signaling. Upstream regulator analysis suggested gene expression changes of forkhead box and hypoxia inducible factor family transcription factors. The established cellular models offer mechanistic insight into cellular changes and therapeutic targets under inhibitor resistance _____________________________________________________________________________________ Zecena et al.
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Background
Cancer drug resistance is a major obstacle to achieve durable clinical responses with targeted therapies. This highlights a need to elucidate the underlying mechanisms responsible for resistance and identify strategies to overcome this challenge. In malignant melanoma, activating point-mutations in the mitogen activated protein kinase (MAPK) pathway in BRAF kinase (B-Raf proto-oncogene, serine/threonine kinase, Gene ID: 673) [1] [2] [3] made it possible to develop potent kinase inhibitors matched to genotyped kinase mutations in precision medicine approaches [4] [5] [6] . In tumors expressing the oncoprotein BRAF(V600E), the inhibitor molecules vemurafenib, dabrafenib, and encorafenib are designed to lock the ATP binding site into an inactive conformation of the kinase [4] , the preferred state of wild-type RAF proteins. Trametinib and cobimetinib are targeting MAP2K7 (MEK, mitogen-activated protein kinase kinase 7, Gene ID: 5609), the BRAF target and down-stream effector molecule. Combinations of single BRAF inhibitors (BRAFi) have proved to be superior to single-agent regimens [7] [8] [9] [10] . For both groups, combinations proved to be superior to single-agent regimens: BRAF inhibitors (BRAFi) in combination with MEK inhibitors (MEKi) improved survival compared to single MAPK inhibitors (MAPKi). However, many patients responding to small molecule inhibition of the MAPK pathway will develop resistance. Ultimately, disease progression will take place and patients relapse with lethal drugresistant disease.
Acquired resistance has been shown to involve a diverse spectrum of oncogenic mutations in the MAPK pathway [11] [12] [13] [14] [15] . In addition, non-genomic activation of parallel signaling pathways was noted [16] . Cell-to-cell variability in BRAF(V600E) melanomas generates drug-tolerant subpopulations. Selection of genetically distinct, fully drug-resistant clones arise within a set of heterogeneous tumor cells surviving the initial phases of therapy due to drug adaptation [17] . Non-genomic drug adaptation can be accomplished reproducibly in cultured cells, and combination therapies that block adaptive mechanisms in vitro have shown promise in improving rates and durability of response [18] . Thus, better understanding of mechanisms involved in drug adaptation is likely to improve the effectiveness of melanoma therapy by delaying or controlling acquired resistance.
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Methods

Cellular models of malignant melanoma
SK-MEL-28 and A375 are human skin malignant melanoma cell lines with BRAF(V600E) activation that are tumorigenic in xenografts [19] [20] [21] [22] (HTB-72 and CRL-1619, American Type Culture Collection, Manassas, VA). The cell lines are maintained in DMEM medium supplemented with 10% fetal bovine serum and antibiotics (10-017-CV, 35-010-CV, 30-002-CI Corning, Corning, NY). All experimental protocols were approved by the Institutional Review Boards at the University of California Merced and Irvine. The study was carried out as part of IRB UCM13-0025 of the University of California Merced and as part of dbGap ID 5094 on somatic mutations in cancer and conducted in accordance with the Helsinki Declaration of 1975.
The vemurafenib-adapted cells were obtained by culturing melanoma cells with incrementally increasing vemurafenib concentrations in the culture media. Starting at 0.25 μM, which matched the naïve half maximal inhibitory concentration (IC50) of the parental cell lines, the vemurafenib concentrations were increased every 7 days in an exponential series up to 100-fold the naïve IC50 concentrations. Following this 6-week selection protocol, BRAFi-resistant (BRAFi-R) models were maintained in media supplemented with 5.0 μM vemurafenib.
Transcriptomic analysis
Total RNA from malignant melanoma cells was extracted using a mammalian RNA mini preparation kit (RTN10-1KT, GenElute, Sigma EMD Millipore, Darmstadt, Germany) and then digested with deoxyribonuclease I (AMPD1-1KT, Sigma EMD Millipore, Darmstadt, Germany). Complementary DNA (cDNA) was synthesized using random hexamers (cDNA SuperMix, 95048-500, Quanta Biosciences, Beverly, MA). The purified DNA library was sequenced using a HighSeq2500 (Illumina, San Diego, CA) at the University of California Irvine Genomics High-Throughput Facility. Purity and integrity of the nucleic acid samples were quantified using a Bioanalyzer (2100 Bioanalyzer, Agilent, Santa Clara, CA). Libraries for next generation mRNA transcriptome sequencing (RNA-Seq) analysis were generated using the TruSeq kit (Truseq RNA Library Prep Kit v2, RS-122-2001, Illumina, San Diego, CA). In brief, the workflow involves purifying the poly-A containing mRNA molecules using oligo-dT attached magnetic beads. Following purification, the mRNA is chemically fragmented into small pieces using divalent cations under elevated temperature. The cleaved RNA fragments are copied into first strand cDNA using reverse transcriptase and random primers. Second strand cDNA synthesis follows, using DNA Polymerase I and RNase H. The cDNA fragments are end repaired by adenylation of the 3' ends and ligated to barcoded adapters. The products are then purified and enriched by nine cycles of PCR to create the final cDNA library subjected to sequencing. The resulting libraries were validated by qPCR and size-quantified by a DNA high sensitivity chip (Bioanalyzer, 5067-4626, Agilent, Santa Clara, CA). Sequencing was performed using 50 base pair read length, single-end reads, and more than 10 7 reads per sample. Raw fasta files were mapped to human reference Genome Reference Consortium GRCh38 using Bowtie alignment with an extended Burrows-Wheeler indexing for an ultrafast memory efficient alignment [23, 24] . Read counts are scaled via the median of the geometric means of fragment counts across all libraries. Transcript abundance was _____________________________________________________________________________________ Zecena et al.
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Since single-end reads were acquired in the sequencing protocol, quantification of reads or fragments yields identical results. Statistical testing for differential expression was performed using Cufflinks, Cuffnorm, and Cuffdiff in the Tuxedo suite [25] and EdgeR in the Bioconductor toolbox [26] . Differentially expressed genes were further analyzed using Ingenuity Pathways Analysis (IPA, Qiagen, Rewood City, CA), classification of transcription factors (TFClass) and gene set enrichment analysis (GSEA, Broad Institute, Cambridge, MA) [27, 28] . Triple replicate samples were subjected to SYBR green (SYBR green master mix, PerfeCTa® SYBR® Green FastMix®, 95072-05k, Quanta Biosciences, Beverly, MA) real time quantitative polymerase chain reaction (RT-qPCR) analysis in an Eco system (Illumina, San Diego). RT-qPCR threshold cycle (CT) values were normalized using multiple housekeeping gene like actin beta (ACTB, GeneBank: 60), cyclophilin A (PPIA, peptidylprolyl isomerase A, GeneBank: 5478) and RNA polymerase II subunit A (POLR2A, GeneBank: 5430). Gene expression profiles were analyzed using the ΔΔCT method. Oligo nucleotides crossing exon-exon-junctions of transcripts served for RT-qPCR validation of RNA-Seq signals of differentially expressed target genes in BRAFi-resistant melanoma cells ( Supplementary table 1 ).
Inhibitor cytotoxicity studies
Chemical BRAFi against BRAF(V600E), vemurafenib, (PLX4032, Selleckchem, Houston, TX) was dissolved in dimethyl sulfoxide (DMSO, Sigma) as 10.0 mM stock solution and used in treatments in final concentrations between 0.01 μM and 50.0 μM. Melanoma control experiments were carried out in the presence of equivalent amounts of DMSO solvent without drug. Cell viability was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, M6494, Thermo Fisher Scientific, Waltham, MA) absorbance assay by subtracting background readout at 650 nm from response readout at 570 nm wavelength. IC50 concentrations were determined after 72 hours of drug treatment between 0.01-100 μM in two-fold dilution series. Analysis was performed using CalcuSyn (2.0, Biosoft, Cambridge, UK).
Melanin quantification
Melanin pigment production of cultured cells was determined by colorimetric measurements normalized for total protein levels in arbitrary units [29, 30] . Melanoma cells were harvested by centrifugation at 3,000 rpm (3830 g, Z326K, Labnet International, Edison, NJ) and dissolved in either 1.0 N NaOH for melanin assay or lysis 250 for protein assay. The cell lysates were sonicated, incubated at room temperature for 24 hours, and cleared by centrifugation at 13,000 rpm for 10 minutes (17,000 g, , Z326K, Labnet International, Edison, NJ). The absorption of the supernatant was measured at OD475 in a spectrophotometer (Smartspec3000, Bio-Rad, Carlsbad, CA). Cells were lysed in mild denaturing conditions in lysis 250 buffer (25 mM Tris, [pH 7.5], 5 mM EDTA, 0.1% NP-40, 250 mM NaCl) containing proteinase inhibitors (10 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml pepstatin, 5 μg/ml antipain, 1 mM phenylmethylsulfonyl fluoride). The total protein amount in the lysates was quantified using a colorimetric Bradford assay (5000001, Bio-Rad, Richmond, CA) at 595 nm and an incubation time of 30 min [31] .
Results
Generation of BRAFi-resistant melanoma cell lines
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The parental melanoma cell lines SK-MEL-28 and A375 were exposed to incrementally increasing concentrations of the mutant-BRAF inhibitor vemurafenib ( Figure 1A ). At the initial inhibitor concentration matching the IC50 of vemurafenib of the naïve parental melanoma cells [32, 11] cell proliferation slowed down. Surviving cells were propagated and subjected to an exponential series of increasing vemurafenib concentrations until BRAFi-R sublines were obtained tolerating at least 5 μM vemurafenib in the culture media with similar cell proliferation rates as the parental cell lines of 0.67 doublings per day.
The BRAFi-R cell lines showed structures typically observed in differentiated melanocytes ( Figure  1B -C). In the presence of 5 μM vemurafenib, however, the parental cells were not able to grow but the resistant cells proliferated comparable to naïve cell lines ( Figure 1D -E). For the SK-MEL-28 cell line, two resistant sublines were established. The resistant sublines displayed IC50 values of 11.5 ± 0.9 μM and 13.3 ± 1.2 μM for SK-MEL-28-BRAFi-R1 and SK-MEL-28-BRAFi-R2 respectively, which is approximately 10-20 fold of the IC50 in a low micro-molar range for the parental cells with 0.74 ± 0.05 μM. For the A375 cell line, the IC50 of the A375-BRAFi-R cell line was observed at 17.7 ± 1.5 μM, 22.7 fold of IC50 for the parental A375 cells with 0.78 ± 0.22 μM ( Figure 1F ).
Transcriptomic profiling identifies non-genomic rewiring of treatment-resistant cancer cells
We conducted transcriptomic profiling of BRAFi treatment resistant SK-MEL-28-BRAFi-R1 and SK-MEL-28-BRAFi-R2 cell lines by RNA-Seq and looked for differential expression versus the parental SK-MEL-28 cell line. 980 unique transcripts showed significant differential expression in RNA-Seq experiments with p-values below 0.05, absolute log-fold change (LOG(FC)) greater or equal 1.0 (Figure 2A-B) . The differentially expressed genes included 505 upregulated transcripts and 475 downregulated transcripts (Supplementary table 2 -3) . We subjected the identified directional sets to pathway enrichment analysis ( Supplementary table 4 ). The following distinct clusters stood out and showed significant enrichment with p-values below 0.05 and q-values below 0.10 ( Figure 2C ). Melanogenesis and pathways in cancer, inflammation, nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and signal transducer and activator of transcription (STAT) signaling, metabolic pathways including alanine, tyrosine, valine, leucine, inositol, one-carbon metabolism, cell-adhesion molecules, neurotrophin signaling were overrepresented in the upregulated dataset. MAPK signaling and epithelial-mesenchymal transition (EMT) were differentially expressed and characterized by strong up-or down-regulation. Extra-cellular matrix (ECM) receptors, cell cycle, and hypoxia signaling were enriched in the downregulated dataset. Of the 980 differential expressed genes, we validated expression changes of 150 genes by RT-qPCR ( Figure 2D , Supplementary table 3 ). 64.0% (96 of 150) of the transcript regulation in treatment resistant melanoma in the RT-qPCR data corresponded significantly in direction with the RNA-Seq data upon treatment resistance with p-values below 0.05. When both treatment resistance models of SK-MEL-28 and A375 were taken into consideration, about half of the tested genes, 50 of 96, showed consistent regulation (Figure 2E, Supplementary table 3 ). Genes in MAPK signaling included nuclear factor of activated T-cells 2 (NFATC2, Gene ID: 4773), phospholipase A2 group VI (PLA2G6, Gene ID: 8398), dual specificity phosphatase 1 (DUSP1, Gene ID: 1843), and dual specificity phosphatase 2 (DUSP2, Gene ID: 1844), which were downregulated in the BRAFi-resistant cells compared to control. Genes contributing to melanogenesis adenylate cyclase 1, (ADCY1, Gene ID: 107), dopachrome tautomerase (DCT, TYRP2, Gene _____________________________________________________________________________________ Zecena et al.
Cancer systems biology and network rewiring of therapy-resistant cancer Page 7 of 20 ID: 1638), and platelet derived growth factor C (PDGFC, Gene ID: 56034) were upregulated. Lastly, metabolic regulators such as methylenetetrahydrofolate dehydrogenase 2, (MTHFD2, Gene ID: 10797) for folate metabolism, asparagine synthetase (ASNS, Gene ID: 440) for amino acid metabolism, and NME/NM23 nucleoside diphosphate kinase 1 (NME1, Gene ID: 4830) and dihydropyrimidine dehydrogenase (DPYD, Gene ID: 1806) for pyrimidine metabolism were significantly upregulated ( Figure  2D ). Taken together, the transcriptomic changes were validated in two distinct melanoma models, SK-MEL-28 and A375, both cell lines with metastatic potential showed differential expression of MAPK signaling while activating alternative receptor interactions and metabolic processes.
Upstream regulator analysis suggests control by transcription factor families
In a next step, we subjected the gene list to hierarchical transcription factor motif analysis. We asked whether any of the enriched transcription factor motif families were represented in the differential gene expression data. In detail, we looked for transcription factors as well as their target genes whose promoters show the respective transcription factor binding sites are among the same list of regulated genes ( Figure 3A) . It is expected that differentially expressed transcription factors show enrichment in significantly deregulated target genes. Further, identified target genes with enriched transcription factor motif will have major contributions to significantly deregulated pathways under treatment resistance ( Figure 3B) . A network illustration of transcriptional master regulators, target genes, and dysregulated effector network upon treatment resistance illustrates transcriptional synergy ( Figure 3C 
Validation of pathway rewiring in drug resistance in multiple cell lines by transcriptomic arrays
Using transcriptome analysis of reversible drug resistance identified distinct pathways that allowed to circumvent BRAF blockage ( Figure 4A ). Cell-to-cell variability in combination with drug exposure selects for distinct sub-populations of MAPKi resistant cell lines. In a hierarchical fashion, transcriptional master regulators promote a distinct set of target genes resulting in circumvention of _____________________________________________________________________________________ Zecena et al.
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MAPK inhibition. Receptor activation by fibroblast growth factor 1 (FGF1, Gene ID: 2246) or platelet derived growth factor C (PDGFC, Gene ID: 56034) can lead to activated receptor tyrosine signaling parallel to canonical MAPK signaling [16] ( Figure 4B ). In addition, downregulation of tumor suppressors reengages mitogenic signaling. The dual specific phosphatases, DUSP1 and DUSP2, have the ability to switch MAPK signaling off but among the top hits of down. Thereby, downregulation of dual specific phosphatases facilitates and reinforces alternative MAPK effector activation under BRAF blockage ( Figure 4B ). One the mitogen-activated protein kinase 1 (MAPK1, ERK2, Gene ID: 5594) effector targets, EPAS1, showed upregulation and the ability to maintain its transcriptional program. Pro-apoptotic program of TGFB3 was downregulated and included SMAD family member 9 (SMAD9, Gene ID: 4093) and DUSP1/2 ( Figure 4C ). Adenylate cyclase, G-protein, and phospholipase signaling are alternative cascade observed in cutaneous and uveal melanoma ( Figure 4D ). Upregulation of ADCY1, endothelin receptor type B (EDNRB, Gene ID: 1910), PLCB4, and cAMP responsive element binding protein 3 (CREB3, Gene ID: 10488) promote MITF activity, the master transcription factor for pigmentation genes. Down-stream metabolic enzymes, TYR and DCT, are both MITF target genes and contribute to enhanced eumelanin production of some MAPKi resistant cells. The observed pigmentation showed a wide range of from 1.3-fold to up to 16.8-fold upregulation ( Figure 4D ). While both cell lines showed dysregulation of melanogenesis, the involved genes were different. SK-MEL-28-BRAFi-R2 has ASIP prominently expressed (TYR (2.1), DCT (2.8), tyrosinase related protein 1 (TYRP1, OCA3, Gene ID: 7306) (0.5), MITF (0.7), agouti signaling protein (ASIP, Gene ID: 434) (18.9)), while A375-BRAFi-R showed strongest regulation of TYRP1 and MITF (TYR (0.34), DCT (0.24), TYRP1 (41.8), MITF (2.94), ASIP (0.41)). In summary, upregulation of growth factors or receptors triggers signaling pathways circumventing BRAF blockage. Changes in amino acid and one-carbon metabolism support cellular proliferation despite inhibitor treatment. In addition, alternative MAPK signaling coincident with differential response of melanogenesis and pigmentation pathways, which partially overlap with MAPK effectors. In particular, NFKB1, REL, ZEB1, FOXO1, and EPAS1 may serve as master regulators to concert broad transcriptional changes implemented in altered cascades of MAPK, TGFB, ADCY, and MITF signaling.
Discussion
Activation of the MAPK pathway is the central and most common oncogenic event in the pathogenesis malignant melanoma [3, 33] . About 50% of all melanoma patients have activating somatic mutations in the activator loop involving L597, T599, V600, and K601 switching BRAF into a constitutively active protein kinase. Such activation is supported by somatic copy number amplifications of chromosome 7 [34] , often coinciding with somatic V600E/G/K/M/R mutations. Another 20-30% of the patients show non-genomic activation of BRAF by transcriptional upregulation or post-translational modification induced by somatic mutations of upstream signaling molecules like KIT proto-oncogene receptor tyrosine kinase (KIT, Gene ID: 3815), neuroblastoma RAS viral oncogene homolog (NRAS, Gene ID: 4893), or lossof-function neurofibromin 1 (NF1, Gene ID: 4763). Constitutively activated BRAF phosphorylates MAPK1 and downstream kinases resulting in mitogenic signaling, proliferation, and cell growth. Integrated into this cellular program is a negative feedback resulting in reduction of NRAS expression [35, 36] .
Genomic sequencing has facilitated the understanding of acquired resistance mechanisms to MAPKis [14, 37, 38, 15, 39, 16, 40] . Detected genetic aberrations included mutations in NRAS, MAPK1/2, _____________________________________________________________________________________ Zecena et al.
Cancer systems biology and network rewiring of therapy-resistant cancer Page 9 of 20 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA, Gene ID: 5290), and phosphatase and tensin homolog (PTEN, Gene ID: 5728). Somatic melanoma mutations provide examples of how single, well-defined genomic events can confer resistance against vemurafenib treatment. In contrast, transcriptomic as well as epigenomic regulation can provide insight into resistance states that may involve larger networks. Eventually, neither genomic nor transcriptomic readout will be supported by a kinome data reporting on resistance states of phosphoproteins that can be modulated by posttranslational modification.
The transcriptomic profiles revealed a network of genes involved in adenyate cyclase signaling conferring resistance and contributing to melanogenesis. ADCY1 and CREB3 are prominent members of the melanogenesis pathway exhibiting mitogenic control and MITF activation. Similarly, a gain-of-function screen confirmed a cyclic-AMP-dependent melanocytic signaling network including G-protein-coupled receptors, adenyl cyclase, protein kinase cAMP-activated catalytic subunit alpha (PRKACA, Gene ID: 5566), and cAMP responsive element binding protein 1 (CREB1, Gene ID: 1385) [41] . The MAPK pathway negatively regulates MITF protein level as well as activity [30] , which in turn regulates a series of cell cycle regulating genes. In particular, P16INK4A and P21CIP1, each gene products of cyclin dependent kinase inhibitor 2A (CDKN2A, Gene ID: 1029) and cyclin dependent kinase inhibitor 1A (CDKN1A, Gene ID: 1026), respectively, differentiation genes TYR, DCT, TYRP1 as well as survival genes B-cell lymphoma 2 apoptosis regulator (BCL2, Gene ID: 596) and BCL2 family apoptosis regulator (MCL1, Gene ID: 4170) are effector genes under the control of MITF. Inhibition of MITF resulted in sensitivity to chemotherapy drugs [42] . In contrast, upregulation of MITF in therapy-resistance may present itself as survival mechanism, which coincides with upregulation of melanin, hence may serve as prognostic biomarker for drug adaptation.
Dual specific phosphatases (DUSPs) act downstream of BRAF on phosphorylated MAPK members to provide attenuation of signal. Loss of DUSP activity results in constitutive activation of the pathway. Prominent members of this family DUSP1 and DUSP2 have consistently been downregulated at the transcriptional level. In prior clinical studies, somatic mutation of DUSP4 in MAPKiR has been reported [39] . Although in that case a genomic mechanism of resistance has been utilized, the outcome of reduced DUSP activity by genomic or transcriptomic changes leads to persistent triggering of MAPK effectors.
Metabolic genes support the rewiring of acquired resistance and have been shown to play an intricate role in the malignancy of skin cutaneous tissues. Glutamine and glucose metabolism showed sensitivity to combinations of MAPKi and metabolic inhibitors in preclinical studies [43] . The transciptomic profiles identified key enzymes in related, branching glycolytic pathways of serine, folate and pyrimidine metabolism. A cancer systems biology analysis of skin cutaneous melanoma brought a new master regulator and diagnostic target in cancer metabolism forward. Somatic mutations of DPYD have the ability to reconfigure and activate pyrimidine metabolism promoting rapid cellular proliferation and metastatic progression [44] .
The forkhead box family of transcription factors is an important downstream target of the MAPK pathway and is currently being considered as new therapeutic targets in cancer, including melanoma therapy [45] . In epithelial cells, these transcriptional factors are directly involved in the expression of cyclin dependent kinase inhibitors and CDKN2A gene under the control of TGFβ [46, 47] . Both, _____________________________________________________________________________________ Zecena et al.
Cancer systems biology and network rewiring of therapy-resistant cancer Page 10 of 20 downregulation of anti-apoptotic targets as well as activation of proliferative metabolism have been observed as mechanisms contributing to MAPKiR. Downregulation of FOXF2 has been shown to promote [48] . In contrast, a different member of the FOX family, the stem cell transcription factor forkhead box D3 (FOXD3) has been identified as an adaptive mediator of the response to MAPK pathway inhibition selectively in mutant BRAF melanomas [49, 50] .
To this point, we have identified non-genomic rewiring of pathways by RNA-Seq data and validated gene candidates in two cell lines by transcriptomic arrays. However, eventually perturbation of the identified resistance pathways by drug molecules or small hairpin RNAs will needed to solidify a translational impact of candidate genes. Nevertheless, the established cell culture models of treatment resistance provide a broadly applicable platform to utilize high-throughput screening tools in search for effective combinations of targeted therapies in cancer.
Conclusion
The MAPK pathway undergoes major rewiring at the transcriptional level while acquiring inhibitor resistance. The outcome of this transcriptional plasticity are different upstream master regulators, while maintaining similar effector genes. Combination therapies including targeted as well as immune checkpoint inhibition are promising and rapidly improving. For these therapies to show durable, progression-free successes in the clinical setting, adaptation mechanisms of treatment resistances need to be understood. Cellular model systems in combination with transcriptome-wide analyses provide insight how non-genomic drug adaptation can be accomplished. Over time a better understanding of mechanisms involved in drug adaptation is likely to improve the effectiveness of melanoma therapy by delaying or controlling acquired resistance. Ongoing efforts are focused on utilizing the established preclinical models to overcome drug adaptation and improve the effectiveness of cancer therapy by delaying or controlling acquired resistance. A) Schematic representation of network involving drug inhibition and non-genomic selection for differential expression of driver genes that can circumvent suppressed signaling. B) Deregulation of MAPK signaling with RNA-Seq data mapped in red and blue for differential upregulation and downregulation, respectively. C) Modulation of TGFB3 signaling leads to downregulation of dual specific phosphatases, which are required to switch MAPK signaling off. D) Interconnectedness between of G-protein signaling and melanogenesis. Alternative activation of melanoma pathways lead to increased eumelanin synthesis and mitogenic survival. Photograph of cell pellets of melanoma cell models and detected melanin. Left shows SK-MEL-28 melanoma cell line, middle and right shows two different SK-MEL-28-BRAFi-resistant melanoma cell lines with elevated melanin production.
